Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Molecularly Driven, Time-limited Treatment With Ropeg-interferon in Newly Diagnosed Patients With JAK2- Mutant Polycythemia Vera - a Multicenter, Single-arm, Phase II Study

NCT07886801 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07886801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Molecularly Driven, Time-limited Treatment With Ropeg-interferon in Newly Diagnosed Patients With JAK2- Mutant Polycythemia Vera - a Multicenter, Single-arm, Phase II Study
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
October 30, 2026
Completion date
October 31, 2029
Enrollment
55 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

jak2 mutation, polycythemia vera (pv)

Arms

As registered; 1 arm.

  • Ropeg-Interferon in People With Polycythemia Vera ExperimentalRopeginterferon

    Each patient will receive ropeg-IFN subcutaneously.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Proportion of patients who meet criteria for treatment discontinuation 24 months

    and sustain the same criteria without treatment re-initiation at month 48

Lead sponsor's other trials

Memorial Sloan Kettering Cancer Center, most recent start first.

Similar trials

Same condition (Polycythemia Vera) and phase, most recent start first.